RYTM Key Statistics, Chart & Performance
The current stock price of RYTM is 101.59 USD. In the past month the price decreased by -3.41%. In the past year, price increased by 80.86%.
RYTM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About RYTM
Company Profile
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The company is headquartered in Boston, Massachusetts and currently employs 283 full-time employees. The company went IPO on 2017-10-05. The firm is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Company Info
RHYTHM PHARMACEUTICALS INC
222 Berkeley Street, 12th Floor
Boston MASSACHUSETTS 02116 US
CEO: David P. Meeker
Employees: 283
Phone: 18572644280
RHYTHM PHARMACEUTICALS INC / RYTM FAQ
What does RYTM do?
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The company is headquartered in Boston, Massachusetts and currently employs 283 full-time employees. The company went IPO on 2017-10-05. The firm is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
What is the stock price of RHYTHM PHARMACEUTICALS INC today?
The current stock price of RYTM is 101.59 USD. The price increased by 2.18% in the last trading session.
Does RHYTHM PHARMACEUTICALS INC pay dividends?
RYTM does not pay a dividend.
How is the ChartMill rating for RHYTHM PHARMACEUTICALS INC?
RYTM has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists RYTM stock?
RYTM stock is listed on the Nasdaq exchange.
Can you provide the short interest for RYTM stock?
The outstanding short interest for RHYTHM PHARMACEUTICALS INC (RYTM) is 8.77% of its float.
RYTM Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to RYTM. When comparing the yearly performance of all stocks, RYTM is one of the better performing stocks in the market, outperforming 91% of all stocks.
RYTM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RYTM. The financial health of RYTM is average, but there are quite some concerns on its profitability.
RYTM Financial Highlights
Over the last trailing twelve months RYTM reported a non-GAAP Earnings per Share(EPS) of -3.1. The EPS increased by 30.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.01% | ||
| ROE | -66.87% | ||
| Debt/Equity | 0.35 |
RYTM Forecast & Estimates
21 analysts have analysed RYTM and the average price target is 138.45 USD. This implies a price increase of 36.28% is expected in the next year compared to the current price of 101.59.
For the next year, analysts expect an EPS growth of 27.27% and a revenue growth 48.07% for RYTM